Single-Fraction Stereotactic Ablative Body Radiotherapy to the Lung- The Knockout Punch

This overview summarises the current evidence on efficacy and safety of single-fraction stereotactic ablative body radiotherapy (SABR) for primary lung cancers and lung metastases, in comparison with the more widely adapted multi-fraction SABR regimens. A literature search using the Medline database through PubMed was carried out using the following key words: ('stereotactic' or 'sabr' or 'sbrt'), ('radiotherapy' or 'radiation therapy'), ('lung' or 'thorax' or 'thoracic' or 'chest'), ('cancer' or 'metasta-' or 'oligometasta-'), alongside: (i) ('single-fraction' or 'single-dose') to identify trials and cohort studies with single-fraction SABR to lung malignant tumours and (ii) ('fraction' or 'schedule') limiting the search to 'clinical trial' and 'randomized controlled trial' to ensure thorough capture of lung SABR trials comparing different fractionations. The review discusses the radiobiological, technical and organ at risk considerations of single-fraction SABR to the lung. (C) 2022 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Automated summary

This overview provides a summary of the current evidence on the efficacy and safety of single-fraction stereotactic ablative body radiotherapy (SABR) for primary lung cancers and lung metastases, compared with multi-fraction SABR regimens. A comprehensive literature search was conducted to identify relevant trials and cohort studies, and the review discusses the radiobiological, technical, and organ at risk considerations of single-fraction SABR for lung treatment.